Analyst Michael Wiederhorn downgraded CVS from Outperform to Perform and removed the $85 price target.
CVS is more of a long-term opportunity, given the timeline needed to execute on its strategy and near-term legacy business challenges, Wiederhorn said in the Monday downgrade note.
The company had made several large acquisitions over the last decade, including Coram and Target Corporation (NYSE: TGT) pharmacies. Going by CVS' history and the magnitude of the Aetna buy, the analyst said he is taking a prudent stance on the near-term outlook for integration.
The long-term opportunity to reduce costs and improve access to care will take years to play out, Wiederhorn said, adding that this could also detract from earnings due to the time and capital required.
The managed care segment will account for only 31 percent of CVS' projected earnings in 2019, with the fortunes of the company still hinging on the less lucrative pharmacy business, the analyst said.
Oppenheimer is "not overly bullish" on the near-term outlook for CVS' retail/long-term care and pharmacy benefit manager businesses, which it said face company-specific pressures from contract movement.
Wiederhorn also sees headwinds from industry pressures and an uncertain reimbursement environment.
"Although the valuation appears attractive by historical levels, we expect these factors to dominate the story for the foreseeable future."
The Price Action
CVS shares were trading up 2.84 percent to $54.31 at the time of publication Monday.
CVS Health Stores To Carry CBD Products From Curaleaf, Elevate
Insider Buys Of The Week: Activision, Arconic, CVS Health
Latest Ratings for CVS
|Apr 2019||BMO Capital||Initiates Coverage On||Outperform|
|Mar 2019||Bernstein||Initiates Coverage On||Outperform|
View More Analyst Ratings for CVS
View the Latest Analyst Ratings
See more from Benzinga
- Diplomat Pharmacy's Valuation Presents Value To A Strategic Buyer, Raymond James Says In Upgrade
- Bernstein Out Bullish On CVS, Sees 40% Upside Potential For Stock
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.